window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : July 13, 2025

  • News
  • About Us
Contact Us

Machine Learning

  • Artificial Intelligence,Biologics & Biosimilars,Cell & Gene Therapy,Clinical Development

    Shift Bioscience tackles AI model flaws to advance rejuvenation discovery

    New study proposes AI-driven framework to refine gene target discovery [...]

    July 4, 2025
  • Artificial Intelligence,Drug Development,Technology and platforms

    Optibrium and TalTech launch EU-funded PhD to advance sustainable drug discovery

    Partnership aims to boost predictive metabolism models using machine learning [...]

    July 2, 2025
  • Artificial Intelligence,CDMOs & Manufacturing,Drug Development,Technology and platforms

    AI can’t thrive in chaos: New survey finds labs still struggling with basics

    A new industry survey has revealed that while life sciences [...]

    June 27, 2025
  • Artificial Intelligence,Biologics & Biosimilars,Drug Development,Rare Diseases

    Game-changing £7.5M prize launches to unlock AI drug targets for ALS

    20 global teams will receive early-stage funding and access to [...]

    June 25, 2025
  • Oncology,Technology and platforms

    Mainz Biomed launches feasibility study to assess pancreatic cancer biomarker panel

    Mainz Biomed has initiated a feasibility study as part of [...]

    June 11, 2025
  • Artificial Intelligence,Clinical Trials,Drug Development,Technology and platforms

    PhaseV and Crohn’s & Colitis Foundation join forces to fast-track IBD clinical trials with AI

    A new collaboration aims to tackle the toughest challenges in [...]

    May 28, 2025
  • Artificial Intelligence,Biologics & Biosimilars,Drug Development

    Alchemab strikes $415m licensing deal with Lilly for ALS candidate ATLX-1282

    UK-based Alchemab Therapeutics has signed a landmark licensing agreement with [...]

    May 20, 2025
  • Artificial Intelligence,Clinical Trials

    PhaseV raises $50M to expand AI-powered clinical trial platform

    PhaseV has secured $50 million in Series A funding to [...]

    May 13, 2025
  • Market Access & Commercialization,Partnerships & Funding

    Alchemab Therapeutics signs $415m licensing deal with Lilly for ALS program

    May 6, 2025
  • Artificial Intelligence

    New cybersecurity breakthrough restores accuracy of breast cancer digital twin to 98%

    April 22, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2025 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Cereno taps global CRO for next big step in pulmonary hypertension drug trial
    Categories: Clinical Trials, Drug Development, Rare Diseases
  • Eleva doses first volunteers with new therapy targeting rare kidney disease
    Categories: Biologics & Biosimilars, Clinical Trials, Drug Development, Rare Diseases
  • First-in-class cell therapy for rare mitochondrial disorder gains FDA fast track
    Categories: Cell & Gene Therapy, Clinical Trials, Rare Diseases, Regulatory Affairs
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top